<DOC>
	<DOCNO>NCT03062644</DOCNO>
	<brief_summary>The MR308-3502 study multicenter double-blind , randomise , placebo- active comparator-controlled study female subject evaluate efficacy safety MR308 acute pain TAH STAH ( total subtotal abdominal hysterectomy ) .</brief_summary>
	<brief_title>Efficacy Safety Randomised Acute Pain Study MR308 : STARDOM2 .</brief_title>
	<detailed_description>This multicenter double-blind , randomise , placebo- active comparator-controlled study female subject evaluate efficacy safety MR308 acute pain total subtotal abdominal hysterectomy ( TAH STAH ) . The screen Visit ( Visit 1 ) take place 28 day plan TAH STAH . The surgery perform Visit 2 . Visit 2 consists three different section , part surgery , surgery post surgery . On next Day ( Visit 3 ) subject qualify participation regular measurement pain . Subjects meet eligibility criterion , define pain level , randomise one six treatment group give IMPs 120h . Subjects randomise screen failure give standard care per local practice . Visits 4 , 5 , 6 ,7 8 , one five day randomisation perform record efficacy safety parameter . The last dose IMP take subject 120h initial dose Visit 8 ( Completion/Discontinuation Visit ) perform . The Adverse Event ( AE ) Follow Visit ( Visit 9 ) last study visit do earlier seven day subject 's last dose IMP . It perform telephone .</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Female subject ≥ 18 year day consent . 2 . Willing able provide write informed consent study . 3 . Subjects schedule total subtotal abdominal hysterectomy general anasethesia via Pfannenstiel incision . 4 . The elective procedure ( total subtotal hysterectomy without salpingooophorectomy ) must benign condition within 28 day screen . Subjects stage 0 carcinoma situ cervix , endometrial hyperplasia clinically stag 1A 1B endometrial cancer allow participate . 5 . American Society Anaesthesiology physical status I II . 6 . If female childbearing potential , must use highly effective method contraception throughout study , breastfeeding , negative pregnancy test prior receive IMP . A highly effective method birth control define one result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilisation , implant , injectables , combine oral contraceptive , IUDs ( Intrauterine Device , hormonal ) , sexual abstinence vasectomise partner ) . 7 . Good general health judge Investigators basis medical history physical examination . 8 . Willingness comply study procedures requirement . Additional Inclusion Criteria Surgery : 1 . Abdominal hysterectomy complete without immediate complication . 2 . Tolerating oral fluid , uncontrolled nausea/vomiting ready take oral analgesia . 3 . The subject alert calm , spontaneously pay attention caregiver , e.g . RASS = 0 ( Sessler et al. , 2002 &amp; Ely et al. , 2003 ) . 4 . Subjects capable sit supine , stand sit position walk 10 meter without assistance morning day follow surgery . 5 . Subjects moderate severe pain ( qualify PIVAS score ≥ 45mm &lt; 70mm ≥ 70mm ≤ 90mm ) result surgical procedure ( abdominal hysterectomy ) general anaesthesia . This must measure within maximum 24 hour leave recovery room subject randomise day surgery , cessation postoperative analgesia . 1 . Any abnormal laboratory value clinically significant opinion Investigator would compromise safety subject study . 2 . Any recent history frequent nausea vomiting , dizziness within last 3 month regardless etiology . 3 . Subjects medical condition treatment either warn contraindication per SmPC tramadol ( e.g . selective serotonin reuptake inhibitor ( SSRIs ) , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) , tricyclic antidepressant , MAO inhibitor ( within 14 day take IMP ) , antipsychotic , anticonvulsant seizure thresholdlowering medicinal product ) , celecoxib ( e.g . increase risk postoperative bleeding , active peptic ulceration , GI bleed inflammatory bowel disease ) paracetamol . 4 . Known sensitivity and/or contraindication tramadol , celecoxib , paracetamol , sulfonamide , opioids , NSAIDS , COX2 inhibitor , related compound formulation excipients well severe hypersensitivity reaction ( e.g . anaphylactic shock , bronchospasm , angioedema ) drug . 5 . Subjects know inadequate pain relief paracetamol , tramadol celecoxib . 6 . Subjects require medication prohibit per section prohibit medication . 7 . Subjects Investigator 's opinion consider increase risk operative ( associated surgical procedure general anaesthesia ) postoperative complication , e.g . excessive postoperative bleeding , infection . 8 . Any history drug alcohol abuse , misuse , physical psychological dependence , mood change , sleep disturbance functional capacity impact pain perception . 9 . Significant neurological psychiatric disorder include mental instability ( unrelated pain ) could interfere pain assessment ; preexist new nonabdominal/pelvic pain might impair assessment nociceptive pain . 10 . Any medical history significant and/or inadequately control cardiovascular ( uncontrolled high blood pressure , high risk cardiovascular event , severe heart failure ) , pulmonary , hematologic , ( include coagulopathy/bleeding disorder ) , neurological ( e.g . subject epilepsy susceptible seizure ) , liver disease ( e.g . severe hepatic impairment ) , kidney disease ( e.g . serum creatinine level great 1.5 time upper limit normal , impaired renal function subject take diuretic , ACEinhibitors , angiotensin II antagonist ) , endocrine , immunologic , dermatologic painful condition condition may compromise ability subject participate study might interfere drug absorption , distribution , metabolism excretion . 11 . Previous randomisation study . 12 . Subjects participate clinical research study involve new chemical entity experimental drug within 30 day study entry ( defined start Screening Period ) . 13 . Subjects treat regularly opioid analgesic NSAIDs within 30 day prior screen receive longacting NSAID within three day prior start surgery . 14 . Subjects incapable comply protocol . 15 . Epidural spinal anaesthesia infiltration wound infusion local anaesthetic agent allow . A single perioperative dose allow . 16 . History ongoing chronic pelvic inflammatory disease painful endometriosis . 17 . History advance gynaecological cancer . Additional Exclusion Criteria Surgery : 1 . Serious complication surgery randomisation , include : Postoperative primary secondary bleed control . Subjects abdominal hysterectomy surgery complete plan . 2 . If Investigator 's opinion , factor may affect compliance protocol . 3 . Subject clinical need antiemetic ( apart standard perioperative practice define protocol ) medication prohibit per section prohibit medication . 4 . Subjects receive analgesic medication perioperative analgesia describe protocol . 5 . Any concern renal function deteriorate , e.g . laboratory parameter , profound hypotension , poor urine output excessive bleeding surgery .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Open Total Subtotal Abdominal Hysterectomy</keyword>
</DOC>